Introduction {#s0005}
============

Lung cancer is the most common cancer type and the leading cause of cancer mortality in China [@b0005], accounting for 19.6% of all newly diagnosed cancer cases [@b0010]. Nearly 85% of lung cancers are non-small-cell lung cancer (NSCLC), which has a 5-year survival rate of 17.1%. The majority of patients diagnosed with NSCLC are found to be at an advanced stage. The overall survival (OS) of patients who fail to respond to conventional anticancer therapies (chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) remains unsatisfactory.

The application of vitamin C for malignant diseases has had a renaissance [@b0015]. Studies [@b0020], [@b0025] have found that high-dose intravenous pharmacological administration of vitamin C produces plasma concentrations 100--1000 times higher than those of healthy nutritional levels and up to 100-fold higher than the maximally tolerated oral intake [@b0030]. Phase I clinical trials show its safety, high tolerability and relief from the side effects of chemotherapy [@b0035], [@b0040]. Clinical trials indicated the potential efficacy of intravenous vitamin C (IVC), with improved performance status or prolonged disease progression/overall time in ovarian [@b0045] and pancreatic cancers [@b0050]. Its synergy with chemotherapy improves quality of life (QoL) [@b0050].

High-dose vitamin C is also applied for lung cancer. It decreases cell proliferation in lung cancer cell lines [@b0055], including mechanisms of cell cycle arrest [@b0060] and apoptosis [@b0065]. Clinical studies [@b0045] suggested that a large dose of IVC can increase the efficacy or reduce the toxic side effects of chemotherapy when used in synergy with chemotherapy. Recently, Schoenfeld [@b0070] presented a phase II study of advanced-stage NSCLC patients (n = 14) treated with IV carboplatin (area under the curve (AUC), 6; 4 cycles), IV paclitaxel (200 mg/m^2^, 4 cycles), and IVC (75 g twice a week, four cycles). No grade 3 or 4 toxicities related to vitamin C were reported. Four out of the 14 patients showed a partial response (PR), 9 out of the 14 patients showed stable disease (SD), and one showed progressive disease (PD), which indicated the potential efficacy of IVC in NSCLC therapy.

Hyperthermia (HT) is a method of treating tumors at the lesion site, which is mainly divided into local, regional, and whole-body HT. It is a complementary cancer treatment, often used in association with chemotherapy or radiotherapy, increasing the efficacy and prolonging the survival time [@b0075], [@b0080]. Takayuki et al [@b0085] suggested that HT and radiotherapy exerted a synergistic effect in the treatment of NSCLC. Modulated electro-hyperthermia (mEHT) is a regional electromagnetic HT method. The major advantage of mEHT is the nano-range energy liberation, rather than overall heating of the target [@b0090]. Due to its high efficacy [@b0090] and the synergy of the electric field [@b0095], the targeted cancer cells absorb the heat that raises the temperature 3 °C higher than the enviorment [@b0100]. Studies have found that the antitumor mechanism of mEHT is as follows: inducing cell apoptosis, improving tumor perfusion, inhibiting tumor angiogenesis and resolving tumor hypoxia [@b0090], [@b0100], [@b0105], [@b0110], [@b0115]. Clinical data show that mEHT has long been used in clinical practice for various malignant diseases, and has clinical results for NSCLC [@b0120], [@b0125], [@b0130]. mEHT can be used alone or in combination with radiotherapy (RT), chemotherapy, and chemoradiotherapy, and a growing number of studies are exploring combinations of mEHT and other therapies [@b0135], [@b0140], [@b0145]. In a retrospective study, 93 patients with advanced NSCLC (stage IIIB-IV) were divided into HT combined with chemotherapy and chemotherapy groups, and the results indicated that HT combined with chemotherapy might lead to the development of a better therapeutic strategy for advanced NSCLC patients with malignant pleural effusion and greatly reduce the toxic effects of chemotherapy on the incidence of weakness and gastrointestinal adverse reactions in advanced NSCLC patients [@b0150]. A multi-institutional prospective randomized trial observed that RT + HT improved local PFS in the treatment of locally advanced NSCLC [@b0155].

In our previous phase I clinical study [@b0160], we found that IVC with simultaneous mEHT is safe and well tolerated, and concomitant application significantly increases the plasma vitamin C level. The average scores for the functioning scale increased continuously, and the average values for symptoms decreased gradually, which indicates that QoL is improved when patients receive the above treatments.

Therefore, we conducted a randomized phase II trial to evaluate the effect of best supportive care (BSC) with or without IVC combined with simultaneous mEHT on tumor response, progression-free survival (PFS) and OS in previously treated patients with refractory advanced (stage IIIb or IV) NSCLC. Herein, we present the results of this trial.

Materials and methods {#s0010}
=====================

Patient recruitment {#s0015}
-------------------

Eligible patients were adults (≥18 years ≤70 years) who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0--2; who had a histologically proven diagnosis of primary NSCLC, stage IIIb or IV; who were not curable with surgery or showed radiographically confirmed PD during previous radiotherapy and/or four to six cycles of platinum-based chemotherapy (mostly cisplatin/carboplatin in combination with vinblastine, etoposide, or paclitaxel); who had failed to respond to targeted therapy or immunotherapy or were intolerant of their latest anticancer therapy regimen; and who showed at least one measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) ([Table 1](#t0005){ref-type="table"}).Table 1Patient baseline characteristics.CharacteristicsActive arm (n = 49)Control arm (n = 48)Age (years) Median6263 Range42--7243--72  Sex Male3837 Female1111  ECOG performance status Grade 02526 Grade 11211 Grade 21211  Stage at study entry Stage IIIB2525 Stage IV2423  Pathology Squamous cell carcinoma2425 Adenocarcinoma2323 EGFR in Adenocarcinoma20  EGFR in Adenocarcinoma EGFR(−)136 EGFR(+)1017  Smoking status Current34 Prior3633 Never1011 Unknown00  Reason for failure of last anticancer therapy Refractory4543 Intolerant45[^2]

Patients were excluded if they showed G6PD deficiency or a history of oxalosis by urinalysis; were receiving anticancer therapies; were diagnosed with a comorbid condition that would affect survival, such as end-stage congestive heart failure, unstable angina or myocardial infarction within 6 weeks prior to the study; or had metallic implants or replacements in the treatment area or implanted electronic devices anywhere in the body.

All patients provided written informed consent. *The study was approved by the Ethics Committee of the Clifford Hospital affiliated with Jinan University. All patients provided written informed consent according to Good Clinical Practice (GCP) and national regulations \[No: 2/2015-10\]*.

Study design and treatment {#s0020}
--------------------------

The study was a single-center, Phase II, randomized clinical trial. Trial Registration: [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir005}, NCT02655913; registration date, 7th Jan 2016. The date of enrollment of the first and last participants in the trial was 17th Jan 2016 and 17th July 2017, respectively, and all participants were recruited by the Clifford Hospital affiliated with Jinan University.

Eligible patients were randomized to receive IVC + mEHT + BSC (active arm) or BSC alone (control arm) ([Fig. 1](#f0005){ref-type="fig"}). BSC included multidisciplinary care, BSC documentation, symptom assessment and symptom management [@b0160]. In the active arm, patients received IVC 1 g/kg·d three times a week for 25 treatments in total. Each milliliter of vitamin C injection contained 3 g of sodium ascorbate and water for injection, with the pH adjusted to 6.5--8.0 with sodium bicarbonate. Vitamin C was infused for 120 min. We used the mEHT method for HT treatment with the EHY2000+ device. This impedance-coupled device works with an amplitude-modulated 13.56 MHz carrier frequency, and its principles and practice are described in our previous study [@b0160]. The treatment regimen of mEHT was 60 min/session; the power of mEHT was gradually increased from 135 W to 150 W depending on the patient's actual tolerance. The applicator used was 7.1 dm^2^. The applied energy range in one session was between 486 kJ and 540 kJ. The patients were placed lying in the prone position, and the treatment covered the complete lung (30 cm diameter circle). The temperature of the treatment area was in the range of 40--42 °C, calculated indirectly by the treatment device. BSC focuses on helping patients obtain relief from symptoms such as nausea, pain, fatigue or shortness of breath.Fig. 1Study design and patient disposition: Eligible patients were randomized to receive IVC + mEHT + best supportive care (active arm) or best supportive care alone (control arm).

The primary endpoint of this study was OS assessed by an independent investigator. Secondary endpoints included PFS, the 3-month disease control rate (DCR) that was defined as the proportion of patients with a complete response (CR) or PR or SD, QoL, and the association between biomarkers and treatment outcome.

Randomization and masking {#s0025}
-------------------------

We used a computer-generated random sequence to allocate patients (nonmasked) to BSC (control arm) or IVC + mEHT + BSC (active arm). The minimization method was used for randomization. When a new subject was added, the unevenness of the distribution of influencing factors in each group was calculated, and then the group of the subject was determined with different probabilities to ensure that the unevenness of the distribution of influencing factors was minimized. Patients were stratified by histology (adenocarcinoma or squamous cell carcinoma), ECOG performance status (ECOG score 0, 1, or 2), Epithelial growth factor receptor (EGFR) mutation in adenocarcinoma, medical records of anticancer therapies in the past 6 months, and stage of cancer.

Best supportive care {#s0030}
--------------------

Since BSC was the control arm in our clinical trial, we designed a BSC program based on the recommendations from Zafar [@b0165]. Patients from the BSC arm received appropriate treatments judged by the team including nurses, physicians, psychologist, and dietitians. Therapeutic measures included antibiotics, analgesic drugs, and dietetic assistance according to actual situations of patients. All the symptoms, supportive or palliative care methods and results were documented. Symptoms were assessed at baseline and throughout the trial in person. The symptom assessment was followed up by telephone every two weeks. Clinical assessment was performed during each hospitalization. Tumor-control assessment was assessed by radiographic examination every three months. Assessment methods are detailed in the study assessments section below. Symptom management was based on the National Comprehensive Cancer Network (NCCN) guidelines.

Study assessments {#s0035}
-----------------

Enhanced chest and abdomen CT scans, brain MRI and bone scans were carried out at baseline and every 4 weeks for the first 12 weeks from the start of the study. All scans were assessed by an independent central radiology review. Response measurements were carried out according to RECIST 1.1. PFS was defined as the time from the onset of the study until disease progression or death from any cause. Three-month DCR was measured 3 months after therapy and defined as the percentage of subjects with a CR, a PR or SD at 3 months relative to all randomly assigned patients. We categorized patients as nonresponding when they had PD; otherwise, patients were categorized as responding. OS was defined as the time from randomization to death due to any cause. Adverse events were recorded, and their severity was assessed according to the Common Terminology Criteria for Adverse Events, version 3.0. To evaluate the maintenance of improvement in the QoL, the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) was used.

Statistical analysis {#s0040}
--------------------

The statistical systems GraphPad Prism 6 and PASS 15 were used for modeling and analysis. The sample size was determined to ensure that appropriate conclusions could be drawn with sufficient confidence. At least eighty-nine candidates were required, considering that a one-sided log-rank test with 45 active participants and 44 control participants achieves 85% power at a 0.05% significance level to detect a hazard ratio (HR) of 0.48 with a median survival time of 5.5 in the control arm for patients of Asian origin [@b0170]. Survival estimates were analyzed using the log-rank test and the Kaplan--Meier method. Evaluation of short term response effects in two arms were examined by χ^2^ test and T test. Comparisons of the study arms considering selected tumor markers and immune-associated factors were conducted using T test and Wilcoxon test. Descriptive statistics were used for treatment administration and safety.

Results {#s0045}
=======

Patient characteristics {#s0050}
-----------------------

Between 2016 and 2017, 97 patients were randomly assigned to receive IVC + mEHT + BSC (n = 49) or BSC alone (n = 48) ([Fig. 1](#f0005){ref-type="fig"}). Demographics and baseline tumor characteristics were comparable between the groups ([Table 1](#t0005){ref-type="table"}). The most common histologies were adenocarcinoma and squamous cell carcinoma. Two cases were adenosquamous carcinoma. EGFR exons 19 (n = 4) and 21 (n = 6) were mutated in the active arm.

Efficacy {#s0055}
--------

The median follow-up time was 24 months. A total of five patients dropped out. Of them, two patients in the active arm experienced cardiac events; one patient suffered severe diarrhea. Two patients were lost to follow-up in the control arm. Efficacy analyses were performed in a modified intention-to-treat population of patients who did not receive other anticancer therapy before the cutoff date (May 1, 2019). Ultimately, based on the intent-to-treat principle, 97 patients were analyzed.

The log-rank test and Kaplan--Meier plots of OS and PFS showed highly significant differences (*P* \< 0.05) between the active and control arms. The median OS was 9.4 months for the active arm and 5.6 months for the control arm \[HR = 0.3268; 95% CI, 0.1582--0.4105; *P* \< 0.0001\]. The median PFS was 3.0 months for the active arm and 1.85 months for the control arm (HR = 0.3294; 95% CI, 0.1222--0.3166; *P* \< 0.0001; [Fig. 2](#f0010){ref-type="fig"}). Neither OS nor PFS were affected by the pathological type of carcinoma (*P* \> 0.05) ([Table 2](#t0010){ref-type="table"}).Fig. 2Progression-free survival time (A) and overall survival time (B): Kaplan--Meier plots for progression-free and overall survival. A. The log-rank test for PFS for the two comparisons: active arm vs control arm \[HR = 0.3294; 95% CI, 0.1222--0.3166; *P* \< 0.0001\]. B. The log-rank test for OS for the two comparisons: active arm vs control arm \[HR = 0.3268; 95% CI, 0.1582--0.4105; *P* \< 0.0001\].Table 2Short-term response effects of squamous cell carcinoma and adenocarcinoma patients in the active arm.ParametersSquamous cell carcinoma\
(n = 24)Adenocarcinoma\
(n = 23)*P* value[\*](#tblfn1){ref-type="table-fn"}3-Month Response PR340.563 SD95 PD12143-Month DCR (PR + SD)1290.561PFS (Median)3 (months)2.9 (months)0.293OS (Median)12.45 (months)10.8 (months)0.616[^3][^4]

By using the RECIST 1.1 criteria, 5 of 49 (10.2%) subjects in the active arm had PR, while no PR was observed in the control arm; 16 of 49 (32.7%) subjects in the active arm and 8 of 48 (16.7%) subjects in the control arm had SD; and 28 of 49 (57.1%) subjects in the active arm and 40 of 48 (83.3%) subjects in the control arm had PD. No CR was observed in both two arms. The 3-month DCR was 42.9% in the treatment arm and 16.7% in the control arm (odds, 95% CI, *P* = 0.0073) ([Table 3](#t0015){ref-type="table"}).Table 3Evaluation of short-term response effects in the active arm and control arm.ParametersActive arm\
(n = 49)Control arm\
(n = 48)*P* value[\*](#tblfn2){ref-type="table-fn"}Number of deaths (%)30 (61.2)46 (95.8)\<0.001  3-Month Response PR (%)5 (10.2)0 (0)0.004 SD (%)16 (32.7)8 (16.7) PD (%)28 (57.1)40 (83.3)3-Month DCR (PR + SD) (%)21 (42.9)8 (16.7)0.0073[^5][^6]

There were no significant differences in 3-month DCR, PFS or OS between adenocarcinoma and squamous cell carcinoma ([Table 2](#t0010){ref-type="table"}) or between EGFR(+) and EGFR(--) subjects ([Table 4](#t0020){ref-type="table"}).Table 4Short-term response effects of EGFR(+) and EGFR(−) patients in the active arm.EGFR in AdenocarcinomaEGFR(+)\
(n = 10)EGFR(−)\
n = 13*P* value[\*](#tblfn3){ref-type="table-fn"}19 (+)\
(n = 4)21 (+)\
(n = 6)3-Month Response PR3000.100 SD123 PD04103-Month DCR (PR + SD)630.072PFS (Median)3 (months)2.9 (months)0.805OS (Median)21.8 (months)7.8 (months)0.253[^7][^8]

None of the patients received further chemotherapy, radiotherapy, targeted therapy or immune therapy. However, in the active arm, four patients received a total of 50 follow-up IVC + mEHT treatments, and three patients received a total of 25 follow-up treatments (once a week).

Adverse effects and toxicity {#s0060}
----------------------------

The overall adverse effects of IVC and mEHT were marginal. Thirst was the major symptom during all of the treatments. Adverse effects were measured in 22/49 (44.9%) of subjects in the active arm. Symptoms disappeared when the treatments ended, except for one patient who experienced severe diarrhea ([Table S1](#s0110){ref-type="sec"}). This patient was withdrawn from the study at the stage when he ended the second combined treatment. Acute toxicity was not observed in other patients at any stage of treatment. No significant differences were registered in full blood count or biochemical and hematologic profiles before and after the treatment.

Quality of life {#s0065}
---------------

The QLQ-C30 scores were recorded over the full cycle of the study. The average scores for the functioning scales increased continuously, so QoL improved ([Table 5](#t0025){ref-type="table"}).Table 5Function subscale and psychometric parameters.ParametersPrior treatmentPost treatment*P* value[\*](#tblfn4){ref-type="table-fn"}*P* value (Active vs Control)[\#](#tblfn4){ref-type="table-fn"}Mean ± SDMean ± SDPrior vs PostPriorPostPhysical Active arm77.69 ± 16.7085.71 ± 15.39\<0.00010.0533\<0.0001 Control arm74.44 ± 13.2159.93 ± 15.35\<0.0001  Role Active arm72.79 ± 24.7073.54 ± 24.310.50000.81190.6919 Control arm71.67 ± 23.4371.39 ± 23.81\>0.9999  Emotional Active arm84.01 ± 20.3388.61 ± 15.750.26330.4408\<0.0001 Control arm83.68 ± 17.3668.86 ± 19.20\<0.0001  Cognitive Active arm85.03 ± 18.4085.03 ± 19.02\>0.99990.18620.1026 Control arm81.25 ± 18.0780.55 ± 17.970.5000  Social Active arm77.89 ± 22.1578.43 ± 21.070.75000.24520.3953 Control arm82.99 ± 19.9081.94 ± 19.700.5000  Global Active arm46.25 ± 20.8574.76 ± 20.11\<0.00010.0635\<0.0001 Control arm52.77 ± 22.1240.49 ± 22.77\<0.0001  Fatigue Active arm46.48 ± 17.5220.63 ± 18.14\<0.00010.0770\<0.0001 Control arm39.93 ± 20.5961.34 ± 25.32\<0.0001  Nausea/vomiting Active arm24.83 ± 22.0811.56 ± 26.180.00080.1460\<0.0001 Control arm18.63 ± 20.2631.94 ± 28.940.0007  Pain Active arm31.18 ± 21.2125.51 ± 27.450.02050.4413\<0.0001 Control arm28.82 ± 20.8447.45 ± 24.55\<0.0001  Dyspnea Active arm38.09 ± 23.5727.21 ± 22.23\<0.00010.4542\<0.0001 Control arm34.03 ± 23.3150.23 ± 26.610.0003  Insomnia Active arm35.37 ± 37.5230.61 ± 30.300.27810.20680.0772 Control arm23.84 ± 26.4343.75 ± 33.09\<0.0001  Appetite loss Active arm29.93 ± 24.7610.20 ± 20.64\<0.00010.4090\<0.0001 Control arm25.00 ± 24.3139.58 ± 26.32\<0.0001  Constipation Active arm23.81 ± 26.354.761 ± 11.78\<0.00010.1395\<0.0001 Control arm17.36 ± 27.5026.16 ± 31.380.0097  Diarrhea Active arm8.843 ± 20.1612.92 ± 24.360.32830.77530.3014 Control arm7.870 ± 19.717.870 ± 19.710.0112  Financial problems Active arm40.14 ± 35.9921.09 ± 20.06\<0.00010.7496\<0.0001 Control arm38.19 ± 30.7456.94 ± 27.47\<0.0001[^9]

In comparison, the differences in physical, emotional and global improvement after 9 weeks of therapy between the control and the active arms were significant. The psychometric parameters (symptoms) decreased gradually in the active arm of the study, despite the advanced NSCLC and the short (nine week) period of study. The symptoms in the control arm became stronger with time. Fatigue, nausea, pain, dyspnea, appetite loss and constipation were decreased significantly between the groups post treatment (negatively, corresponding to a decrease in symptoms). Note that no significant difference between the groups prior to treatment was observed.

Biomarker analysis {#s0070}
------------------

No significant differences in tumor markers, such as CEA, SCC, CA15-3, and CYFRA21-1, were observed before and after treatment or between the treatment and control arms ([Table S2](#s0110){ref-type="sec"}).

Inflammation markers {#s0075}
--------------------

The statistical evaluation shows some significant changes in inflammatory immune factors. The complete comparison of the arms to each other shows more significance than the changes in the individual groups. IL-6 was not different in the two arms before the treatment (*P* = 0.9413) but differed significantly after therapy (*P* = 0.0033) and was lower in the active arm ([Table 6](#t0030){ref-type="table"}). The difference originated from the active arm therapy (*P* = 0.0046), while the value in the control arm was nearly constant (*P* = 0.1317) ([Table 6](#t0030){ref-type="table"}). The same was also observed for C-reactive protein (CRP); prior to therapy, the two arms were equal (*P* = 0.7835), but after therapy, they were significantly different (*P* = 0.0205) ([Table 6](#t0030){ref-type="table"}). The value in the control arm was also unchanged (*P* = 0.0729). TNF-α did not significantly change between evaluations prior to and after treatment or between the arms of the study after therapy ([Table 6](#t0030){ref-type="table"}).Table 6Inflammation markers in the active arm and control arm.Prior treatmentPost treatment*P* value[\*](#tblfn5){ref-type="table-fn"}*P* value (Active vs Control)[\#](#tblfn5){ref-type="table-fn"}Mean ± SDMean ± SDPrior vs PostPriorPostIL-6 Active arm9.962 ± 6.4086.674 ± 4.5360.00460.94130.0033 Control arm10.03 ± 6.50610.08 ± 6.4360.1317  CRP Active arm24.42 ± 28.4514.43 ± 24.700.01340.78350.0205 Control arm24.99 ± 28.6825.30 ± 29.210.0729  TNF-α Active arm10.68 ± 23.388.777 ± 7.7710.49300.71800.6782 Control arm8.827 ± 10.358.963 ± 10.340.1012[^10]

Discussion {#s0080}
==========

IVC and mEHT are widely used by integrative cancer practitioners for many years. To our knowledge, no studies have been reported on mEHT combined with high-dose vitamin C in the treatment of tumors. Our phase I clinical study demonstrated that mEHT significantly improved QoL of NSCLC patients with less side effects [@b0160].

This study shows that PFS and OS in the active arm were significantly improved compared with those in the control arm. The overall 3-month DCR was 42.9% with combination therapy, which was significantly higher than that with BSC alone (16.7%), indicating that our active therapy of IVC + mEHT may be an option for advanced NSCLC patients.

The reasons why there is a significant survival benefit are unclear, and we suspect two possible explanations. The first possibility is that the concomitant application of mEHT with IVC significantly increases the plasma concentration of vitamin C compared to that in the sole or nonconcomitant application of the treatments, which was proven by our phase I clinical trial [@b0160]. Previous studies [@b0060], [@b0175] demonstrated that vitamin C in pharmacologic concentrations generated H~2~O~2~, which selectively affected cancer cell lines but not normal cells. The increased VitC level can generate a high concentration of H~2~O~2~, which can react with the increased labile iron pools in cancer cells to mediate Fenton chemistry and cause oxidative damage to cellular DNA, protein, and lipids, resulting in an energy crisis and cell death [@b0070]. Saitoh et al found that vitamin C combined with HT inhibited the growth of Ehrlich ascites tumor (EAT) cells through G2/M arrest and apoptosis induction via H~2~O~2~ generation at lower vitamin C concentrations, but the same concentration of vitamin C alone didn't exert the carcinostatic effect [@b0180]. The results show that the combination of vitamin C and HT can induce synergic carcinostatic effects. Conventional HT often induces massive necrosis, while mEHT may avoide this outcome by its highly-selective nanoscopic heating [@b0095]. One study indicated that mEHT produced a much higher apoptosis rate by selectively depositing energy on the cell membrane, compared with conventional capacitive coupling hyperthermia [@b0105]. We suspect that the concentration of VitC is significantly increased by mEHT, which is key to attacking cancer cells.

However, in the active arm, we did not find any differences in 3-month DCR, PFS or OS between adenocarcinoma and squamous cell carcinoma or between EGFR(+) and EGFR(-) subjects. The mechanisms need to be addressed, which may be due to the small sample size of each group after stratification.

The second possibility is that IVC + mEHT can modulate the cancer inflammatory microenvironment. The cytokine IL-6 is the bridge connecting cancer cells to the inflammatory environment [@b0185]. Clinical studies have indicated that an increased concentration of IL-6 is strongly associated with increased tumor size and poor prognosis in patients sufering from NSCLC [@b0190], [@b0195], so it may be a potential target in cancer therapy. Cancer inflammation is accompanied by angiogenesis and an inflammatory microenvironment, which is also an independent prognostic marker of poor clinical outcome in NSCLC patients [@b0190], [@b0195]. Welc et al detected HT up-regulated IL-6 level in an animal model [@b0200]. While some studies indicated vitamin C treatment attenuated synthesis of IL-6 [@b0205], [@b0210]. In this study, we found that IL-6 level significantly decreased after 25 treatments in the active arm, and was significantly lower than that in the control arm.

Marsik [@b0215] indicated that candidates with an increased level of CRP have a 28-fold increase in cancer-related death risk. Our study showed that CRP level also significantly decreased after 25 treatments, compared with the control arm. This is similar to the result observed by Mikirova [@b0220], who found that IVC can suppress inflammation, as indicated by reduced CRP levels.

Meanwhile IVC + mEHT could significantly increase the functional scales and significantly decrease the symptom scales, so that QoL improved in these advanced NSCLC patients. Only mild adverse symptoms, such as thirst, fatigue and diarrhea were seen in the active arm. Symptoms (except for one patient with diarrhea) disappeared when the treatments ended.

In addition, 7 patients in the active arm felt better when they finished 25 treatments, and they spontaneously came to our center to receive another 25 to 50 follow-up treatments (once a week). We noticed that 4 of them (2 received 25 follow-up treatments and 2 received 50 follow-up treatments) had a tendency of longer survival time (OS: 38, 38, 37, and 32 months) than other candidates.

Conclusion {#s0085}
==========

Overall, IVC has been shown to be safe and can produce various beneficial effects in nearly all kinds of cancer patients alone and in combination with chemotherapies. To our knowledge, this is the first study to evaluate the efficacy of IVC + mEHT for previously treated patients with refractory advanced (stage IIIb or IV) NSCLC who received BSC treatment. In summary, IVC + mEHT is well tolerated, significantly improves QoL, prolongs PFS and OS, and moderates cancer-related inflammation, so it is a feasible treatment in advanced NSCLC.
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